Advanced Breast Protocols

BRE-026 Paclitaxel albumin bound (Abraxane® Pazenir®) v6

BRE-030 Everolimus and exemestane v4

BRE-032 Pertuzumab (IV), trastuzumab (IV) & docetaxel for locally advanced or metastatic breast cancer v9

BRE-037 Trastuzumab Emtansine (Kadcyla®) MBC v4

BRE-039 Trastuzumab SC (Herceptin®) and capecitabine v1

BRE-041 Docetaxel & Trastuzumab (SC) v1

BRE-043 Paclitaxel and Trastuzumab (sub cut) for Metastatic Breast Cancer v3

BRE-062 Palbociclib with Letrozole v6

BRE-063 Ribociclib with an Aromatase Inhibitor for locally advanced/metastatic breast cancer v5

BRE-067 Atezolizumab (IV) with paclitaxel albumin bound (Abraxane® / Pazenir®) v5

BRE-068 Abemaciclib and Fulvestrant v3

BRE-072 Ribociclib and Fulvestrant v3

BRE-073 Palbociclib and Fulvestrant v3

BRE-074 Carboplatin (AUC 5) v1

BRE-078 Phesgo® (pertuzumab/trastuzumab SC) & docetaxel for locally advanced or metastatic breast cancer v1

BRE-084 Trastuzumab deruxtecan (Enhertu®) v3

BRE-086 Tucatinib trastuzumab (sc) and capecitabine v2

BRE-087 Pembrolizumab in combination with paclitaxel v3

BRE-088 Pembrolizumab (IV) with paclitaxel albumin bound (Abraxane®/ Pazenir®) v5

BRE-090 Sacituzumab govitecan v1

BRE-091 Alpelisib and fulvestrant v1

BRE-100 Talazoparib tosylate v3

BRE-101 Phesgo® (pertuzumab/trastuzumab SC) & weekly paclitaxel for locally advanced or metastatic breast cancer v2

BRE-102 Elacestrant v1

BRE-103 Capivasertib with fulvestrant v1

MULTI-008 Paclitaxel v1
MULTI-018 Larotrectinib v2

MULTI-019 Entrectinib v2

MULTI-029 Olaparib v3

MULTI-033 Capecitabine v1